Figure 9.
Effect of systemic therapy with erbB2-specific CR–bearing lymphocytes on the survival of mice with LuCaP-35 bone tumors. (A and B) Survival data of SCID mice bearing established LuCaP-35 bone tumors (n = 10 mice per group) systemically treated with TNP- or erbB2-specific CR–bearing lymphocytes or medium and preconditioned with 2 Gy TBI (A) or cyclophosphamide (B).